Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Kageji, Teruyoshi*; Mizobuchi, Yoshifumi*; Nagahiro, Shinji*; Nakagawa, Yoshinobu*; Kumada, Hiroaki
Proceedings of 12th International Congress on Neutron Capture Therapy (ICNCT-12), p.62 - 63, 2006/10
We compared and evaluated BNCT radiation dose using JAERI Computational Dosimetry System (JCDS) between BSH-base intra-operative BNCT and BSH, BPA-based non-operative BNCT. In comparison of BNCT radiation dose, BSH-based intra-operative BNCT was 1.4-2.1 times higher than BSH, BPA-basednon-operative BNCT.
Kageji, Teruyoshi*; Mizobuchi, Yoshifumi*; Nagahiro, Shinji*; Nakagawa, Yoshinobu*; Kumada, Hiroaki
Proceedings of 12th International Congress on Neutron Capture Therapy (ICNCT-12), p.60 - 61, 2006/10
We compared and evaluated boron neutron capture therapy (BNCT) radiation dose between gold wire measurement and JAERI Computational Dosimetry System (JCDS). Gold wire analysis demonstrates the actual BNCT dose though it dose not reflect the real the maximum and minimum dose in tumor tissue. We can conclude that JCDS is precise and high-reliable dose planning system for BNCT.
Matsuda, Masahide*; Yamamoto, Tetsuya*; Nakai, Kei*; Endo, Kiyoshi*; Kumada, Hiroaki; Kageji, Teruyoshi*; Matsumura, Akira*
Proceedings of 12th International Congress on Neutron Capture Therapy (ICNCT-12), p.40 - 42, 2006/10
To describe the failure patterns and survival seen with high-grade glioma treated with BNCT, the dose distribution and the clinical responses were retrospectively analyzed. BSH-based BNCT was performed in 12 patients with high-grade glioma (grade IV 7, grade III 5). The post-diagnosis median survival time of 12 patients was 19.8 months (range 3.3-47.2). Four cases of local control, 3 of local recurrence, 3 of distant intraparenchymal recurrence and 2 of subarachnoid dissemination were recorded. According to the analysis of the failure patterns, minimum GTV dose of 26 GyEq or more is necessary for local control.
Kageji, Teruyoshi*; Mizobuchi, Yoshifumi*; Nagahiro, Shinji*; Nakagawa, Yoshinobu*; Kumada, Hiroaki
Proceedings of 12th International Congress on Neutron Capture Therapy (ICNCT-12), p.35 - 36, 2006/10
We analyzed the correlation between boron neutron capture therapy (BNCT) radiation dose and histopathological findings of autopsy or salvage surgery. For the complete remission of glioblastoma (GBM) after BNCT, minimum gross tumor volume (GTV) and clinical target volume (CTV) dose should be 65 and 45 Gy-Eq as a JAERI Computational Dosimetry System (JCDS) dose.
Kageji, Teruyoshi*; Nagahiro, Shinji*; Matsuzaki, Kazuhito*; Mizobuchi, Yoshifumi*; Toi, Hiroyuki*; Nakagawa, Yoshinobu*; Kumada, Hiroaki
International Journal of Radiation Oncology, Biology, Physics, 65(5), p.1446 - 1455, 2006/08
Times Cited Count：32 Percentile：64.47(Oncology)Clinical trials for boron neutron capture therapy (BNCT) for malignant glioma were performed with thermal-epithermal mixed neutron beam generated by JRR-4. The first protocol (P1998) prescribed a maximal gross tumor volume (GTV) dose of 15 Gy since 1998, and then the protocol was applied to 8 patients. In 2001, a dose-escalated protocol (P2001) was introduced, which prescribed a maximal vascular volume dose of 15 Gy, or alternatively, a clinical target volume (CTV) dose of 18 Gy, the protocol was applied to 11 patients. The GTV and CTV doses in P2001 were 1.1-1.3 times greater than those in P1998. The maximal vascular volume dose of those with acute radiation injury was 15.8 Gy. The mean GTV and CTV dose in long-term survivors with glioblastoma was 26.4 and 16.5 Gy, respectively. A statistically significant correlation between the GTV dose and median survival time was found. In the 11 glioblastoma patients in P2001, the median survival time was 19.5 months and 1- and 2-year survival rate was 60.6 % and 37.9 %, respectively. Dose escalation contributed to the improvement in clinical outcome. To avoid radiation injury, the maximal vascular volume dose should be 
12 Gy. For long-term survival in patients with glioblastoma after boron neutron capture therapy, the optimal mean dose of the GTV and CTV was 26 and 16 Gy, respectively. This report introduces principle of BNCT and the activities for the BNCT clinical trials using JRR-4 in JAEA, and the clinical outcomes of the trials under the protocols and radiation injury in the irradiation are described.
Kageji, Teruyoshi*; Nagahiro, Shinji*; Mizobuchi, Yoshifumi*; Toi, Hiroyuki*; Nakagawa, Yoshinobu*; Kumada, Hiroaki
Applied Radiation and Isotopes, 61(5), p.1063 - 1067, 2004/11
Times Cited Count：10 Percentile：54.14(Chemistry, Inorganic & Nuclear)no abstracts in English
Kumada, Hiroaki; Yamamoto, Kazuyoshi; Yamamoto, Tetsuya*; Nakai, Kei*; Nakagawa, Yoshinobu*; Kageji, Teruyoshi*; Matsumura, Akira*
Applied Radiation and Isotopes, 61(5), p.1045 - 1050, 2004/11
Times Cited Count：14 Percentile：64.27(Chemistry, Inorganic & Nuclear)To carry out the BNCT clinical trials based on accurate dosimetry of several absorbed doses given to a patient, we have developed JCDS which can determine the absorbed doses by numerical simulation. The aim of this study is to improve the accuracy of the BNCT dosimetry efficiently. We have developed the multi-voxel calculation method reconstructing the original voxel model by combining of several voxel cell sizes such as in 5mm, 10mm and 20mm voxel cell. To verify the accuracy of the multi-voxel method, the calculation results were compared with the phantom experimental data. These results proved that the multi-voxel calculation enables JCDS to more accurately estimate the absorbed doses to a patient by efficient calculations.
Nakagawa, Yoshinobu*; Pooh, K. H.*; Kobayashi, Toru*; Kageji, Teruyoshi*; Uyama, Shinichi*; Matsumura, Akira*; Kumada, Hiroaki
Journal of Neuro-Oncology, 62(1), p.87 - 99, 2003/04
Times Cited Count：141 Percentile：83.87(Oncology)Our concept of boron neutron capture therapy (BNCT) is selective destruction of tumor cells using the heavy-charged particles Yielded through 10B(n, alpha)7 Li reactions. In the analysis of side effects due to radiation, we included all the 159 patients treated between 1977 and 2001. With respect to the radiation dose (i.e. physical dose of boron n-alpha reaction), the new protocol prescribes a minimum tumor volume dose of 15Gy or, alternatively, a minimum target volume dose of 18Gy. The maximum vascular dose should not exceed 15Gy (physical dose of boron n-alpha reaction) and the total amount of gamma rays should remain below 10Gy, including core gamma rays from the reactor and capture gamma in brain tissue. The outcomes for 10 patients who were treated by the new protocol using a new mode composed of thermal and epithermal neutrons are reported.
Kumada, Hiroaki; Yamamoto, Kazuyoshi; Torii, Yoshiya; Matsumura, Akira*; Yamamoto, Tetsuya*; Nose, Tadao*; Nakagawa, Yoshinobu*; Kageji, Teruyoshi*; Uchiyama, Junzo
JAERI-Tech 2003-002, 49 Pages, 2003/03
JAERI-Tech-2003-002.pdf:5.22MB
no abstracts in English
Nakagawa, Yoshinobu*; Pooh, K. H.*; Kageji, Teruyoshi*; Uyama, Shinichi*; Kobayashi, Toru*; Sakurai, Yoshinori*; Matsumura, Akira*; Yamamoto, Tetsuya*; Kumada, Hiroaki
Research and Development in Neutron Capture Therapy, p.1113 - 1116, 2002/09
To make a new protocol using epithermal neutron beam for high-grade glioma patients, we elucidated the relationship between the radiation dose, histological tumor grade, and clinical outcome. One hundred and eighty-three patients with kinds of brain tumors were treated by BNCT since 1968, however, we performed a retrospective study of 105 patients with glial tumors treated in Japan between 1978 and 1997. As for the radiation side effect, we analyzed all patients(n=159) treated between 1977 and 2001. Ten patients with glioblastoma were treated according to the new protocol using epithermal neutron.
Kumada, Hiroaki; Yamamoto, Kazuyoshi; Matsumura, Akira*; Yamamoto, Tetsuya*; Kageji, Teruyoshi*
no journal, ,
no abstracts in English
